Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Immune memory responses differ between SARS-CoV-2 and influenza A

Researchers in Canada have shown that the long-lasting immunity that develops following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by different T cell responses than those observed for influenza A virus-specific immune memory.

14 Jun 2021

Researchers examine the importance of time after COVID-19 vaccination

A new study has been published on the medRxiv* preprint server, which deals with the importance of time post-vaccination based on the quantification of VOC immune evasion. The current study developed a toy model to estimate the effectiveness of the vaccines against VOC over time. Researchers have shown that the estimated value is highly dependent on time post-vaccination. Additionally, this model can describe the implications of changes in vaccine efficacy against VOC.

14 Jun 2021

Robust immunity against SARS-CoV-2 with Pfizer vaccine is mediated by memory B cells

A reassuring study, released as a preprint on the medRxiv* server, from a multi-institutional team of researchers in Italy suggests that with the Pfizer-BioNTech BNT162b2 vaccine, post-vaccination immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is both robust and durable.

14 Jun 2021

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

A new study, released as a preprint on the bioRxiv* server, presents a new monoclonal antibody (MAb) called DZIF-10c that powerfully neutralizes SARS-CoV-2, including the current variants of concern (VOCs). With high bioavailability in the lungs and wide distribution in the body, the antibody was able to prevent SARS-CoV-2 infection in mice after intranasal administration.

14 Jun 2021

Fatty acid binding site on SARS-CoV-2 spike triggers spike monomer crosstalk that is key to infectivity

A new study, released as a preprint on the bioRxiv* server, examines the role played by a fatty acid called linoleic acid (LA) that attaches at a binding site near the receptor-binding domain (RBD) of the spike protein. The spike exists as a homotrimer in open or closed conformations. In the former, at least one RBD points upwards.

14 Jun 2021

The Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards

The Native Antigen Company, part of LGC Clinical Diagnostics, won ‘The Best COVID-19 Responder’ at OBN 2020 Awards.

From The Native Antigen Company 14 Jun 2021

Study reveals maternal and neonatal benefits of Pfizer COVID-19 mRNA vaccine

A new commentary, published as an ‘In-Press Preview’ in the Journal of Clinical Investigation, addresses the salient issue of vaccination against the coronavirus disease (COVID-19) in pregnancy and potential antibody transfer to the fetus – and provides the evidence in support of messenger RNA (mRNA) vaccine safety and efficacy for both maternal and child health.

13 Jun 2021

Study shows poor antibody response in naive elderly of nursing homes after mRNA vaccination

A new study describes inadequate antibody responses to the Pfizer/BioNTech vaccine against coronavirus disease 2019 (COVID-19) in elderly residents of a care home with no prior history of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to those with such a history. This adds to the current understanding of vaccine efficacy against infection.

13 Jun 2021

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

A new study, released on the bioRxiv* preprint server, supports the efficacy of the wildtype ChAdOx1 nCoV-19 (AZD1222) vaccine against B.1.351, B.1.617.1 and B.1.617.2, while showing that a booster dose of vaccine based on the B.1.351 spike induces further increase in antibody titers.

11 Jun 2021

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Researchers at the U.S. Centers for Disease Control and Prevention (CDC) detected delayed and reduced antibody and T cell responses after immunization with BNT162b2 or the Pfizer-BioNTech COVID-19 vaccine in older adults compared with healthcare workers in Germany.

11 Jun 2021

NCCN experts provide new guidance on COVID-19 vaccines for cancer patients

The National Comprehensive Cancer Network® (NCCN®) today announced the publication of new guidance on COVID-19 vaccines for people with cancer, intended to clear up confusion for patients and caregivers. The new four-page patient guide is based on the latest expert review of evolving evidence.

11 Jun 2021

Study: cis P-tau is an early marker of vascular dementia, Alzheimer's disease

Researchers remain perplexed as to what causes dementia and how to treat and reverse the cognitive decline seen in patients.

11 Jun 2021

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged.

10 Jun 2021

Discovery suggests new pathways for safeguarding the immune system’s ability to fight cancer

In order for cancer to grow and spread, it has to evade detection by our immune cells, particularly specialized "killer" T cells.

10 Jun 2021

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

In a new study by researchers in the UK, the activity of neutralizing antibodies collected from the sera of individuals that contracted COVID-19 during the first wave of the pandemic is tested against variants of concern the B.1.1.7 (or UK) variant and the B.1.351 (or South African) variant, demonstrating somewhat reduced potency of neutralization towards these strains.

10 Jun 2021

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

A team of scientists in Estonia has recently evaluated the therapeutic/prophylactic efficacy of anti-SARS-CoV-2 polyclonal antibodies derived from the colostrum of immunized cows.

10 Jun 2021

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

A new study suggests that the rollout of vaccines against the COVID-19 pandemic may be significant not only in preventing infections by SARS-CoV-2 but other endemic and pandemic-potential coronaviruses (CoVs) as well.

10 Jun 2021

New article explains the pros and cons of nasal vaccines

Vaccines are mostly synonymous with needles, an efficient and effective way to provide immunity to myriad infections. As COVID-19 vaccination efforts roll out across the U.S. and the world, some experts believe that a vaccine administered through the nose could be just as effective and easier to administer.

10 Jun 2021

Study reports on the immunogenicity of single-shot COVID-19 vaccine against SARS-CoV-2 variants

In the three months since Johnson & Johnson's COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention.

9 Jun 2021

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

An opinion paper by researchers from the US and Italy recently discussed various aspects of monitoring anti-SARS-CoV-2 antibodies before and after receiving COVID-19 vaccination to highlight the pros and cons of this monitoring strategy. This paper is published in the open-access journal Diagnostics.

9 Jun 2021

Antibody News and Research

Further Reading

Immune memory responses differ between SARS-CoV-2 and influenza A

Researchers examine the importance of time after COVID-19 vaccination

Robust immunity against SARS-CoV-2 with Pfizer vaccine is mediated by memory B cells

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

Fatty acid binding site on SARS-CoV-2 spike triggers spike monomer crosstalk that is key to infectivity

The Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards

Study reveals maternal and neonatal benefits of Pfizer COVID-19 mRNA vaccine

Study shows poor antibody response in naive elderly of nursing homes after mRNA vaccination

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

NCCN experts provide new guidance on COVID-19 vaccines for cancer patients

Study: cis P-tau is an early marker of vascular dementia, Alzheimer's disease

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Discovery suggests new pathways for safeguarding the immune system’s ability to fight cancer

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

New article explains the pros and cons of nasal vaccines

Study reports on the immunogenicity of single-shot COVID-19 vaccine against SARS-CoV-2 variants

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

Accelerating therapeutic antibody discovery and development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo